---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-004628"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2026-09-28T12:46:22+00:00"
generated_at: "2026-10-12T13:32:10.997762+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Silexion reports positive preclinical findings for SIL204 showing lipoprotein-mediated uptake in KRAS-driven cancers

## Summary
- SIL204 produced robust, dose-dependent mutant KRAS gene silencing in carrier-free assays; serum lipid depletion significantly reduced knockdown efficiency (P < 0.001).
- Exogenous human LDL did not alter silencing potency versus complete serum alone, indicating physiological lipoprotein levels suffice without artificial nanoparticles.
- CSDO Mitchell Shirvan cited LDL receptor upregulation in cancer cells; CEO Ilan Hadar highlighted the Phase 2/3 pancreatic program and systemic subcutaneous delivery.
- Silexion is advancing SIL204 through Phase 2/3 in locally advanced pancreatic cancer, with site initiation at Tel Aviv Sourasky Medical Center and regulatory clearances in Germany.

## SEC filing metadata
- accession: 0001178913-26-004628
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2026-09-28T12:46:22+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891326004628/0001178913-26-004628-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891326004628/zk2636165.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-004628
- JSON: https://secwatch.observer/filing/0001178913-26-004628.json
- Plain text: https://secwatch.observer/filing/0001178913-26-004628.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.